GSK Acquires Bellus Health for $2 billion, Gaining Control of Experimental Cough Medicine

GSK will gain access to Bellus Health's camlipixant, a drug in late-stage development to treat chronic cough.
GSK is paying $14.75 per share for Bellus Health, more than double the company's closing stock price.
GSK expects camlipixant to receive approval in 2026 and generate significant sales through 2031.
The deal strengthens GSK's drug pipeline and is expected to boost the company's earnings per share starting in 2027.
GSK believes camlipixant could become a best-in-class treatment for chronic cough with blockbuster sales potential.